The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The test may mitigate potential interference during immunofixation tests that measure a patient’s response to a multiple myeloma therapy.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.